PharmaLogic to Acquire Lantheus Radiopharmaceutical Manufacturing Facility
Key Points
- PharmaLogic Holdings agreed to acquire Lantheus' CDMO business and radiopharmaceutical manufacturing facility in Springfield, New Jersey, for its Agilera therapeutic CDMO business.
- The deal includes a long-term supply agreement for Agilera to manufacture lutetium Lu 177 dotatate for Lantheus; financial terms were not disclosed.
- PharmaLogic says the addition creates the first transatlantic therapeutic CDMO platform with an established commercial track record in radioligand therapies.
PharmaLogic Holdings has agreed to acquire Lantheus Holdings’ contract development and manufacturing (CDMO) business and radiopharmaceutical manufacturing facility in Springfield, New Jersey, in a move that will expand its U.S. therapeutic manufacturing footprint and establish a transatlantic platform for radioligand therapies (RLTs).
The deal includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus. The acquisition includes the Springfield site’s manufacturing operations, research and clinical development capabilities, and experienced workforce, which will become part of PharmaLogic’s Agilera therapeutic CDMO business. Financial terms were not disclosed.
PharmaLogic says the addition will create the first transatlantic therapeutic CDMO platform with an established commercial track record in radioligand therapies, providing customers with support from early clinical development through commercial manufacturing and global supply.
Agilera brings more than 15 years of experience supporting RLT development and commercialization and currently supplies an alpha therapy to more than 30 countries. The Springfield facility will add U.S. manufacturing capacity as demand for radiopharmaceutical treatments continues to grow.
“This acquisition strengthens Agilera’s unique capabilities in radioligand therapies and expands our capacity in the U.S.,” says Etienne Montagut, president and CEO of PharmaLogic.
Lantheus CEO Mary Anne Heino says PharmaLogic’s existing radiopharmaceutical expertise and manufacturing relationship with the company made it a suitable long-term owner for the facility. The supply agreement is intended to maintain production of Lantheus’ newly approved radiotherapeutic.
For more information, visit pharmalogicgroup.com.
Total Page Views: 2
